Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the following new medicine which was referred to the Minister of Health under the provisions of section 24(5) of the Act and is set out in the Schedule hereto:
Schedule
Product: Strattera
Active Ingredient: Atomoxetine hydrochloride 11.43mg equivalent to 10mg atomoxetine
Dosage Form: Capsule
New Zealand Sponsor: Eli Lilly and Company (NZ) Limited
Manufacturer: Lilly del Caribe, Inc., Carolina, Puerto Rico
Product: Strattera
Active Ingredient: Atomoxetine hydrochloride 20.57mg equivalent to 18mg atomoxetine
Dosage Form: Capsule
New Zealand Sponsor: Eli Lilly and Company (NZ) Limited
Manufacturer: Lilly del Caribe, Inc., Carolina, Puerto Rico
Product: Strattera
Active Ingredient: Atomoxetine hydrochloride 28.57mg equivalent to 25mg atomoxetine
Dosage Form: Capsule
New Zealand Sponsor: Eli Lilly and Company (NZ) Limited
Manufacturer: Lilly del Caribe, Inc., Carolina, Puerto Rico
Product: Strattera
Active Ingredient: Atomoxetine hydrochloride 45.71mg equivalent to 40mg atomoxetine
Dosage Form: Capsule
New Zealand Sponsor: Eli Lilly and Company (NZ) Limited
Manufacturer: Lilly del Caribe, Inc., Carolina, Puerto Rico
Product: Strattera
Active Ingredient: Atomoxetine hydrochloride 5.71mg equivalent to 5mg atomoxetine
Dosage Form: Capsule
New Zealand Sponsor: Eli Lilly and Company (NZ) Limited
Manufacturer: Lilly del Caribe, Inc., Carolina, Puerto Rico
Product: Strattera
Active Ingredient: Atomoxetine hydrochloride 68.56mg equivalent to 60mg atomoxetine
Dosage Form: Capsule
New Zealand Sponsor: Eli Lilly and Company (NZ) Limited
Manufacturer: Lilly del Caribe, Inc., Carolina, Puerto Rico
Dated this 22nd day of April 2008.
JOHN HAZELDINE, Acting Deputy Director-General, Sector Accountability and Funding Directorate (pursuant to delegation given by the Minister of Health on 6 July 2001).